British pharmaceutical company GSK has agreed to pay $2.3 billion to settle lawsuits alleging that its heart burn medication Zantac caused cancer. GSK has settled 80,000 Zantac lawsuit. Watch to know ...

Zantac was pulled from shelves in 2019 amid panic that a key ingredient - ranitidine - could cause cancer, plunging GSK and ...

The announcement confirms an earlier Reuters report that it was closing in on a sale estimated at around $16.41bln ...

Traders around the word awaited U.S. inflation data for September—and the implications it will have for rate cuts at the ...

UNILEVER is finally calling quits on selling ice creams to Russia, two and a half years after Putin’s invasion of Ukraine. The FTSE 100 giant has come under pressure for funding the Kremlin’s war ...

GSK shares rose after the British drug major agreed to pay up to $2.2 billion to settle thousands of U.S. lawsuits over claims its discontinued heartburn medicine Zantac caused cancer. Write to Rob ...

As one of the largest pharmaceutical and vaccine companies, GSK has used its vast resources to create the next generation of healthcare treatments. The company's innovative new product lineup and ...

RSV vaccine sales from GSK and Pfizer have dropped significantly following revised CDC guidelines, narrowing the eligible age ...

GSK’s $2.2 billion Zantac settlement today put its shares top of the FTSE 100, albeit still well short of their level before litigation started in summer 2022. The drugs group rose 5% or 77.5p to 1535 ...

Lawyers representing 10 groups of plaintiffs, or 80,000 liability cases across the US, have backed the payout. There remain another few thousand cases not covered by the payout. GSK will also pay a ...

The UK's main stock indexes slipped on Thursday as some of the companies traded without the entitlement of their dividend pay ...

Dupilumab, an injectable interleukin (IL)-4 and IL-13 pathway inhibitor, recently received FDA approval as the first-ever ...